Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
We evaluated time course relationships between statin-mediated reduction in atherogenic apolipoprotein B (ApoB)-containing particles and dynamic intravascular remodeling of ApoAI-containing lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome.
|
29574070 |
2019 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
This translated into a greater proportion of individuals achieving non-HDL-C < 100 mg/dL (64.6% alirocumab/23.8% UC [DM-DYSLIPIDEMIA]; 65.4% alirocumab/14.9% placebo [DM-INSULIN]) and ApoB < 80 mg/dL (75.1% alirocumab/35.4% UC and 76.8% alirocumab/24.8% placebo, respectively) versus control at week 24 (all P < 0.0001).
|
31706300 |
2019 |
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
While exposing the polygenic architecture of circulating lipids and the underpinnings of dyslipidaemia, these genome-wide association studies (GWAS) have provided further evidence of the critical role that lipids play in coronary heart disease (CHD) risk, as indicated by the 2.7-fold enrichment for macrophage gene expression in atherosclerotic plaques and the association of 25 loci (such as PCSK9, APOB, ABCG5-G8, KCNK5, LPL, HMGCR, NPC1L1, CETP, TRIB1, ABO, PMAIP1-MC4R, and LDLR) with CHD.
|
29800275 |
2018 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial.
|
29381796 |
2018 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, the performance of LDL-C using this new method (LDL-N) is compared with LDL-C estimated with Friedewald equation (LDL-F) in familial combined hyperlipidemia (FCHL), a common primary dyslipidemia in which apolipoprotein B containing particle composition is abnormal and interferes with LDL-C estimation.
|
29970255 |
2018 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Selected dyslipidemia guidelines recommend non-high-density lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (apoB) as secondary targets to the primary target of low-density lipoprotein-cholesterol (LDL-C).
|
29506984 |
2018 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The prevalence of dyslipidemia, with elevations in total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), and apolipoprotein B (ApoB), and a reduction in low-density lipoprotein (LDL) levels are about 30% at the diagnosis of SLE rising to 60% after 3 years.
|
28168401 |
2017 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we focus on dyslipidemia drug targets traceable to human genetic studies, including statins and ezetimibe, as well as promising new classes such as inhibitors of proprotein convertase subtilisin kexin 9, apolipoprotein B, microsomal triglyceride transfer protein, cholesteryl ester transfer protein, angiopoietin-like proteins types 3 and 4 and apolipoprotein C-III.
|
28109622 |
2017 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Common variants in OGFOD3 and APOB as well as rare and common BAD variants were significantly (p<0.05) associated with dyslipidemia.
|
29126409 |
2017 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The apolipoprotein B (APOB) gene has been reported to be a candidate gene for individual susceptibility to dyslipidemia and obesity.
|
25837208 |
2015 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Relationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia.
|
26345861 |
2015 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Several studies have identified APOB as a candidate gene predisposing individuals to dyslipidemia.
|
25292352 |
2014 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In individuals with mixed dyslipidemia rare synonymous variants within LPL gene were associated with attenuated response to FA therapy while APOCIII rare variants were associated with a modest effect on APOB response to FA-statin therapy.
|
24704626 |
2014 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
In this article we reviewed some of the current therapeutic targets for the treatment of dyslipidemia, with a primary focus on endothelial lipase and lecithin cholesterol acyl transferase for raising HDL-C, and the proprotein convertase subtilisin-like kexin type 9 (PCSK9), microsomal triglyceride transfer protein, and the messenger RNA of apolipoprotein B for lowering LDL-C.
|
24334831 |
2014 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The current study reinforces the current knowledge that carrying APOB rs693 is an independent risk factor for dyslipidemia and higher LDL levels.
|
23247049 |
2013 |
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In the present study, the case of an 18‑year‑old male who presented with MS characteristics with central obesity (overweight and a waist circumference of 95 cm) and dyslipidemia (high TG, low HDL levels and low apoA‑I/apoB‑100) was reported.
|
23921547 |
2013 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Purpose of this review is to discuss the available data on the effects of various ASO used for the treatment of dyslipidemia, with the main focus on ASO against ApoB-100, the most advanced in clinical development, and on PCSK9.
|
21418033 |
2011 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
IR and associated dyslipidaemia are the major determinants of low-density apoB-associated LVP in fasting plasma.
|
20940286 |
2011 |
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Association of polymorphisms at restriction enzyme recognition sites of apolipoprotein B and E gene with dyslipidemia in children undergoing primary nephrotic syndrome.
|
18512131 |
2009 |
Dyslipidemias
|
0.400 |
Therapeutic
|
group |
CTD_human |
Atherogenic dyslipidemia is associated with increased levels of chylomicrons and their remnants containing 3 main components: apolipoprotein B-48, triglycerides and cholesterol ester of intestinal origin.
|
18230960 |
2008 |
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease.
|
17462654 |
2008 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
LHGDN |
ApoB100-LDL acts as a metabolic signal from liver to peripheral fat causing inhibition of lipolysis in adipocytes.
|
19020660 |
2008 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The link between hepatic insulin signaling and apolipoprotein B (apoB) production has important implications in understanding the etiology of metabolic dyslipidemia commonly observed in insulin-resistant states.
|
17288985 |
2007 |
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The present study has shown that the S1 allele of APOC3 SstI polymorphism and the H- allele of LPL HindIII polymorphism might have a small effect on apoB levels in the Central European Caucasian population with dyslipidemia of metabolic syndrome.
|
16343038 |
2006 |
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
After 40 weeks of 40 mg atorvastatin treatment decreases in total cholesterol, triglycerides, and apolipoprotein B of 40%, 43%, and 41%, respectively, were observed in the combined dyslipidaemia group, and of 46%, 40%, and 43% in the dysbetalipoproteinaemic patients.
|
12181212 |
2002 |